| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Trisalus Life Sciences, Inc.'s insiders have reduced their positions by a net 937 shares worth roughly $4K.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 1.64M | $5.71M | - | |
| Dir | 1.32M | $4.60M | - | |
| CEO | 1.07M | $3.74M | - | |
| Dir | 542.8K | $1.89M | - | |
| CFO | 261.1K | $908.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | Jennifer Stevens69 | Chief Regulatory Officer | Sell | 3,530 | $4.11 | $14,509.08 | -2.8% | +1.9% | - | |
| Mar 16, 2026 | Richard Marshak68 | Chief Commercial Officer | Sell | 3,457 | $4.11 | $14,209.66 | -3.0% | +1.9% | - | |
| Mar 16, 2026 | Jodi Devlin69 | Chief of Clinical Operations | Sell | 3,207 | $4.11 | $13,171.30 | -3.2% | +1.9% | - | |
| Mar 16, 2026 | Bryan F. Cox57 | Chief of Research | Sell | 3,184 | $4.11 | $13,085.45 | -1.9% | +1.9% | - | |
| Feb 23, 2026 | David Patience | Chief Financial Officer | Buy | 3,657 | $4.10 | $14,993.70 | +1.4% | -35.5% | - | |
| Feb 23, 2026 | Gary B. Gordon | Director | Buy | 9,756 | $4.10 | $39,999.60 | New | -35.5% | - | |
| Feb 23, 2026 | William Valle | Director | Buy | 30,487 | $4.10 | $124,996.70 | New | -35.5% | - | |
| Feb 23, 2026 | Mary T Szela52 | CEO and President | Buy | 30,487 | $4.10 | $124,996.70 | +4.1% | -35.5% | - | |
| Feb 23, 2026 | Michael P Stansky | Director | Buy | 361,098 | $4.10 | $1,480,501.80 | +57.7% | -35.5% | - | |
| May 19, 2025 | Bryan F. Cox57 | Chief of Research | Sell | 4,764 | $5.18 | $24,677.52 | -3.8% | -6.2% | -39.2% |